C. Diliberti

发表

Optimal adaptive sequential designs for crossover bioequivalence studies

Donald J. Schuirmann, Timothy H. Montague, Charles Audet, 2015, Pharmaceutical statistics.

Sequential design approaches for bioequivalence studies with crossover designs

Donald J. Schuirmann, C. Diliberti, D. Potvin, 2008, Pharmaceutical statistics.

A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream

C. Diliberti, C. Hendy, James H. Liu, 2011, Menopause.

Model‐Informed Drug Development and Review for Generic Products: Summary of FDA Public Workshop

C. Diliberti, R. Lionberger, A. Hooker, 2018, Clinical pharmacology and therapeutics.

Public Workshop Summary Report on Fiscal Year 2021 Generic Drug Regulatory Science Initiatives: Data Analysis and Model‐Based Bioequivalence

C. Diliberti, V. Lukacova, A. Rostami-Hodjegan, 2020, Clinical pharmacology and therapeutics.

Osteogenesis imperfecta congenita. A presentation of 16 cases and review of the literature.

C. Diliberti, Freda Vj, Vosburgh Gj, 1961 .

Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive.

C. Diliberti, C. Hendy, K. Reape, 2008, Contraception.

Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.

C. Diliberti, C. Hendy, Marya B Margolis, 2011, Contraception.

The best targets for biogenerics

C. Diliberti, Charles E. Diliberti, 2006 .